The record
Written from the 1 report below. Nothing here is unsourced.
- US President Donald Trump has announced that tariffs of up to 200% will be imposed on imported generic drugs, but only after a two-year zero-tariff period starting August 1, followed by 100% tariffs in the third year.
- The stated aim is to push generic pharma manufacturing back to the US, with penalties for companies that fail to set up plants within the given timeline.
- India, which exported about $9.7 billion of generic drugs to the US in 2025 and supplies roughly one in five generic medicines used in America, faces no immediate impact because of the two-year duty-free window.
- The announcement gives Indian drugmakers time to adjust their strategies, such as expanding US manufacturing or partnering with local companies, before the tariffs take effect.
What to watch next
- Whether Indian pharma companies announce plans to expand manufacturing in the US during the two-year zero-tariff period.
- Any formal US notification or implementation details of the tariff schedule starting August 1.
- Whether Trump follows through on the 100% tariff in year three and the increase to 200% thereafter.
Coverage1
1 report
Indian-language1
All filed from India
Named United States · India · Canada · Donald Trump · Global Trade Research Initiative · TRUTH Social · U.S. Food and Drug Administration
The 1 report is listed beside the record.
Ask this story
Answers cite the reports above, or say they can't.